AR125090A1 - MASKED ACTIVABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS - Google Patents

MASKED ACTIVABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS

Info

Publication number
AR125090A1
AR125090A1 ARP220100601A ARP220100601A AR125090A1 AR 125090 A1 AR125090 A1 AR 125090A1 AR P220100601 A ARP220100601 A AR P220100601A AR P220100601 A ARP220100601 A AR P220100601A AR 125090 A1 AR125090 A1 AR 125090A1
Authority
AR
Argentina
Prior art keywords
activable
masked
methods
related compositions
cytokine
Prior art date
Application number
ARP220100601A
Other languages
Spanish (es)
Inventor
Sayantan Mitra
Nicole G Lapuyade
Hikmat Haizar Assi
Madan M Paidhungat
Dylan L Daniel
Scolan Erwan Le
Walter A Bogdanoff
Na Cai
Hsin Wang
Alexey Yevgenyevich Berezhnoy
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of AR125090A1 publication Critical patent/AR125090A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee construcciones de citoquinas activables que incluyen: (a) una primera construcción monomérica que comprende una primera máscara peptídica (PM1), un tercer resto escindible (CM3), una primera proteína citoquina madura (CP1), un primer resto escindible (CM1), y un primer dominio de dimerización (DD1), en donde el CM1 está ubicado entre la CP1 y el DD1, y el CM3 está ubicado entre la PM1 y la CP1; y (b) una segunda construcción monomérica que comprende una segunda proteína citoquina madura (CP2), un segundo resto escindible (CM2), y un segundo dominio de dimerización (DD2), donde el CM2 está ubicado entre la CP2 y el DD2, donde: el DD1 y el DD2 se unen entre sí; y donde la ACC se caracteriza por una reducción en al menos una actividad de la CP1 y/o la CP2 en comparación con un nivel de control de dicha al menos una actividad de la CP1 y/o la CP2.The present invention provides activatable cytokine constructs including: (a) a first monomeric construct comprising a first peptide mask (PM1), a third cleavable residue (CM3), a first mature cytokine protein (CP1), a first cleavable residue ( CM1), and a first dimerization domain (DD1), where CM1 is located between CP1 and DD1, and CM3 is located between PM1 and CP1; and (b) a second monomeric construct comprising a second mature cytokine protein (CP2), a second cleavable residue (CM2), and a second dimerization domain (DD2), where CM2 is located between CP2 and DD2, where : DD1 and DD2 join each other; and wherein the ACC is characterized by a reduction in at least one CP1 and/or CP2 activity compared to a control level of said at least one CP1 and/or CP2 activity.

ARP220100601A 2021-03-16 2022-03-16 MASKED ACTIVABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS AR125090A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163161913P 2021-03-16 2021-03-16

Publications (1)

Publication Number Publication Date
AR125090A1 true AR125090A1 (en) 2023-06-07

Family

ID=86988807

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100601A AR125090A1 (en) 2021-03-16 2022-03-16 MASKED ACTIVABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS

Country Status (1)

Country Link
AR (1) AR125090A1 (en)

Similar Documents

Publication Publication Date Title
BR112022020440A2 (en) ACTIVATIVE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS
BR112021023814A2 (en) CYSTEINE PROTEASE INHIBITORS AND METHODS OF THEIR USE
AR125090A1 (en) MASKED ACTIVABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS
CL2019002178A1 (en) Low pH pharmaceutical composition comprising antibody constructs that activate t lymphocytes.
BR112023018735A2 (en) MASKED ACTIVABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS
TWD222923S (en) Shoe
MY150685A (en) Molecules for blocking the infections by flaviviruses
DE59306474D1 (en) AC CONTROLLER
Murdoch et al. Proteolytic mechanisms in the ovulatory folliculo-luteal transformation
TWD223791S (en) Shoe
TWD225212S (en) Shoe
AR127274A1 (en) CONSTRUCTIONS OF ACTIVABLE CYTOKINES, AND COMBINATION METHODS
TWD221398S (en) Shoe
Yoon et al. NPCC4: Climate change, energy, and energy insecurity in New York City
MX2024004300A (en) Activatable cytokine constructs and related compositions and methods.
MX2024004301A (en) Activatable cytokine constructs and combination methods.
CN208608971U (en) A kind of gallium nitride microwave integrated circuit pulse modulated circuit
Murakami et al. Synovial fluid matrix metalloproteinase-2 and-9 activities in dogs suffering from joint disorders
ITRM20010336A1 (en) DIRECT RECOMBINANT HUMAN ANTIBODY AGAINST HEPATITIS C VIRUS NON-STRUCTURAL PROTEIN NS3 (HCV), CODING NUCLEIC ACID AND USES
BR112022021828A2 (en) CYTOKINE IMMUNOTHERAPY
MX2022010160A (en) Combination treatment of stroke with plasmin-cleavable psd-95 inhibitor and reperfusion.
AR127275A1 (en) CONSTRUCTIONS OF ACTIVABLE CYTOKINES AND RELATED COMPOSITIONS AND METHODS
ES2123669T3 (en) DERIVATIVES OF THE PLASMINOGEN THAT ARE ACTIVATED WITH THROMBIN.
BR112021018124A2 (en) Cell line comprising selection marker and uses thereof for protein production
CN210579323U (en) Xenon lamp luminescence control circuit